Skip to main content
Fig. 3 | Alzheimer's Research & Therapy

Fig. 3

From: Pharmacokinetic and pharmacodynamic assessment of oral nicotinamide in the NEAT clinical trial for early Alzheimer’s disease

Fig. 3

Segregation of 12 month plasma and CSF nicotinamide and methyl-nicotinamide into drug unelevated (≤ 2.1 μM) and drug elevated (> 2.1 μM) classes. A Plasma nicotinamide averages based on these classifications. B Plasma methyl-nicotinamide averages based on plasma nicotinamide elevated participants. C CSF nicotinamide averages for the participants with elevated CSF nicotinamide. D CSF methyl-nicotinamide averages based on CSF nicotinamide elevated participants. E Correlation of CSF nicotinamide concentration after 12 months of treatment to plasma nicotinamide among drug elevated participants (blue circle is level of non-elevated participants) A poor linear fit is shown (black dashed line). F Correlation of CSF nicotinamide concentration with CSF methyl-nicotinamide. G Ratio of CSF nicotinamide to CSF methyl-nicotinamide depend on whether nicotinamide was elevated in the plasma

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193